Advanced Analytical Technologies, Inc. (AATI) is Part of Rewriting CRISPR Workflow
Published: Wednesday, September 21st, 2016
Tags: CRISPR, Fragment Analyzer
AATI Application Scientist discusses heteroduplex cleavage assay for CRISPR in recent GEN Article
Large scale CRISPR workflows require efficient and accurate screening for successful editing events. Dr. Kyle Luttgeharm, Application Scientist at AATI, details the use of heteroduplex cleavage assays with the Fragment AnalyzerTM Automated CE System as a high throughput screening protocol in a recent gene therapy feature in GEN.
The article also discusses how CRISPR could provide vast improvements to gene therapy over previous methods and its impact on the treatment of several genetic diseases. This next generation gene editing strategy enables sophisticated modifications that will push gene therapy forward as an increasingly viable option for the treatment of genetic diseases.
Read the article in its entirety…